|
gptkbp:instanceOf
|
gptkb:drug
gptkb:insulin
|
|
gptkbp:approvalYear
|
1996
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:A10AB04
|
|
gptkbp:brand
|
gptkb:Admelog
gptkb:Humalog
|
|
gptkbp:CASNumber
|
133107-64-9
|
|
gptkbp:category
|
rapid-acting insulin
|
|
gptkbp:developedBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:differenceFromHumanInsulin
|
proline and lysine at positions 28 and 29 reversed
|
|
gptkbp:duration
|
2 to 4 hours
|
|
gptkbp:eliminationHalfLife
|
about 1 hour
|
|
gptkbp:hasMolecularFormula
|
C257H383N65O77S6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Insulin lispro
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
binds to insulin receptor
|
|
gptkbp:onset
|
15 minutes
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:product
|
recombinant DNA
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
intravenous injection
|
|
gptkbp:sideEffect
|
gptkb:hypoglycemia
allergic reactions
lipodystrophy
|
|
gptkbp:storage
|
2–8°C (refrigerated)
|
|
gptkbp:usedFor
|
gptkb:diabetes_mellitus_type_2
diabetes mellitus type 1
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:insulin
|
|
gptkbp:bfsLayer
|
6
|